Table 1.

Correlation between SLC29A1 expression and clinical characteristics of patients with HCC

	Low SLC29A1 expression (n=204)	High SLC29A1 expression (n=189)	P-value*
Sex
Female	26	24	1.000
Male	178	165
Age, years
≤ 50	94	103	0.107
> 50	110	86
HBsAg
Negative	37	33	0.896
Positive	167	156
HCV
Negative	202	182	0.094
Positive	2	7
Cirrhosis
No	38	34	0.897
Yes	166	155
AFP, ng/mL
≤ 20	89	52	0.001*
> 20	115	137
Tumor encapsulation
Complete	122	111	0.838
None	82	78
Tumor size, cm
≤ 5	111	120	0.081
> 5	93	69
Tumor number
Single	164	150	0.803
Multiple	40	39
Microvascular invasion
No	145	151	0.047*
Yes	59	38
Tumor differentiation
I-II	140	117	0.169
III-IV	64	72
CLIP
0	159	150	0.806
1	45	39
ALT
≤ 75 U/L	185	171	1.000
> 75 U/L	19	18
Child
A	192	182	0.354
B	12	7
BCLC
A	156	152	0.391
B	48	37

Abbreviations: HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, α-fetoprotein; CLIP, Cancer of the Liver Italian Program; ALT, alanine transaminase; BCLC, Barcelona Clinic Liver Cancer.

^* P-values < 0.05 were considered statistically significant.

The Pearson chi-square test was used for between-group comparisons.